keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer her2+ recurrence

keyword
https://www.readbyqxmd.com/read/29773414/hypofractionated-whole-breast-irradiation-with-or-without-boost-in-elderly-patients-clinical-evaluation-of-an-italian-experience
#1
Maria Carmen De Santis, Francesca Bonfantini, Francesca Di Salvo, Alba Fiorentino, Michela Dispinzieri, Mariangela Caputo, Serena Di Cosimo, Gabriella Mariani, Massimiliano Gennaro, Vito Cosentino, Milena Sant, Emanuele Pignoli, Riccardo Valdagni, Laura Lozza
PURPOSE: To examine local control, disease-free survival (DFS), and toxicity in elderly (≥ 65 years) breast cancer patients treated with hypofractionated radiotherapy (hypo-RT) with or without a boost to the tumor bed. PATIENTS AND METHODS: The study was conducted on 752 patients treated from April 2009 to February 2017. Patients received 42.4 Gy in 16 daily fractions (2.65 Gy per fraction). A boost was only administered in cases of grade 3 primary tumor and close or positive margins...
April 22, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29772459/tyrosine-kinase-inhibitors-for-brain-metastases-in-her2-positive-breast-cancer
#2
REVIEW
Renata Duchnowska, Sibylle Loibl, Jacek Jassem
Approximately 30-50% of advanced HER2-positive breast cancer patients will develop central nervous system (CNS) metastases, with an annual risk of around 10%, and a half of them will die from brain progression. An increased risk of brain metastases is also seen in patients with early HER2-positive breast cancer administered curative therapy. Brain metastases in HER2-positive breast cancer patients usually constitute the first site of recurrence. The administration of anti-HER2 monoclonal antibodies, trastuzumab and pertuzumab, considerably delays the onset of symptomatic brain disease: however, the limited penetration of these compounds into the CNS hinders their efficacy...
May 9, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29759595/her2-positive-lobular-versus-ductal-carcinoma-of-the-breast-pattern-of-first-recurrence-and-molecular-insights
#3
Lucia Da Ros, Anna Moretti, Patrizia Querzoli, Massimo Pedriali, Laura Lupini, Cristian Bassi, Paolo Carcoforo, Massimo Negrini, Antonio Frassoldati
BACKGROUND: Infiltrating lobular carcinoma (ILC) represents about 10% of breast cancer and rarely shows overexpression of human epidermal growth factor receptor 2 (HER2). We compared biological and clinical characteristics of HER2-positive ILC versus HER2-positive infiltrating ductal carcinoma (IDC). PATIENTS AND METHODS: We retrospectively analyzed the data of 328 patients with HER2-positive pure ductal or lobular breast carcinoma, comparing clinical and biological data at diagnosis as well as outcome between the 2 histologies...
April 18, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29758480/analytical-and-clinical-performance-of-progesterone-receptor-antibodies-in-breast-cancer
#4
Benjamin C Calhoun, Brian Mosteller, Daniel Warren, Margie Smith, J Jordi Rowe, Christopher P Lanigan, Karen C Mrazeck, Espen Walker, Amy Hanlon Newell, Raymond Jones
OBJECTIVE: Comparison of analytical and immunohistochemical performance of progesterone receptor (PR) antibodies with correlation to recurrence of invasive breast cancer treated with endocrine therapy. METHODS: The binding-affinity kinetics of PR clones 1E2, 1A6, 16 and 636 were compared using synthetic peptides derived from identified epitopes on a Biacore T200. A cohort of 351 cases (Hormone Receptor (HR)+/HER2-) were stained for PR expression with immunohistochemistry (IHC) and scored according to ASCO/CAP criteria...
February 27, 2018: Annals of Diagnostic Pathology
https://www.readbyqxmd.com/read/29753961/the-role-of-parp-inhibition-in-triple-negative-breast-cancer-unraveling-the-wide-spectrum-of-synthetic-lethality
#5
REVIEW
Marios Papadimitriou, Giannis Mountzios, Christos A Papadimitriou
Triple-negative breast cancer (TNBC) accounts for approximately 15-20% of all breast cancers and is characterized by a lack of immunohistochemical expression of estrogen receptors (ER), progesterone receptors (PR) and HER2. TNBC is associated with poor long-term outcomes compared with other breast cancer subtypes. Many of these tumors are also basal-like cancers which are characterized by an aggressive biological behavior with a distant recurrence peak observed early at 3 years following diagnosis. Furthermore, metastatic TNBC bears a dismal prognosis with an average survival of 12 months...
May 2, 2018: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29753042/application-of-e75-peptide-vaccine-in-breast-cancer-patients-a-systematic-review-and-meta-analysis
#6
REVIEW
Reyhane Chamani, Peyman Ranji, Maryam Hadji, Azin Nahvijou, Ebrahim Esmati, Ali Mohammad Alizadeh
The E75 peptide vaccine, derived from tumor-associated antigen HER2, is the most frequently studied anti-HER2 vaccination strategy for the treatment of breast cancer patients. It has been investigated in the several phases Ι/Π of the clinical trials and is currently being evaluated in a randomized multicenter phase III clinical trial. We conducted a systematic review and meta-analysis to clarify the outcomes of the E75 peptide vaccine including the therapeutic efficacy, the disease recurrence, the survival rate, and the side effects...
May 9, 2018: European Journal of Pharmacology
https://www.readbyqxmd.com/read/29745076/ten-years-of-using-adjuvant-trastuzumab-in-breast-cancer-in-serbia-single-institution-experience
#7
Ana Cvetanovic, Sladjana Filipovic, Nikola Zivkovic, Lazar Popovic, Milos Kostic, Miodrag Djordjevic, Aleksandar Karanikolic, Dane Krtinic
PURPOSE: The purpose of this study was to determinate disease-free interval (DFI) and overall survival (OS) in HER2-positive breast cancer patients who received adjuvant trastuzumab at the University Clinic of Nis, Serbia, and to investigate the influence of clinicopathological and biological characteristics of the tumor on prognosis. The second aim was to determinate the most frequent cause for the treatment discontinuation, recurrence rate, as well as the site of most common localization of the first recurrence of disease...
March 2018: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/29743588/notch-1-pten-erk1-2-signaling-axis-promotes-her2-breast-cancer-cell-proliferation-and-stem-cell-survival
#8
Andrew Baker, Debra Wyatt, Maurizio Bocchetta, Jun Li, Aleksandra Filipovic, Andrew Green, Daniel S Peiffer, Suzanne Fuqua, Lucio Miele, Kathy S Albain, Clodia Osipo
Trastuzumab targets the HER2 receptor on breast cancer cells to attenuate HER2-driven tumor growth. However, resistance to trastuzumab-based therapy remains a major clinical problem for women with HER2+ breast cancer. Breast cancer stem cells (BCSCs) are suggested to be responsible for drug resistance and tumor recurrence. Notch signaling has been shown to promote BCSC survival and self-renewal. Trastuzumab-resistant cells have increased Notch-1 expression. Notch signaling drives cell proliferation in vitro and is required for tumor recurrence in vivo...
May 10, 2018: Oncogene
https://www.readbyqxmd.com/read/29738653/-prognostic-factors-in-patients-with-breast-cancer-and-brain-metastasis-as-the-first-site-of-recurrence
#9
Alejandro Mohar-Betancourt, Alberto Alvarado-Miranda, Juan Alejandro Torres-Domínguez, Paula Cabrera, Fernando Lara-Medina, Yaudim Sadid Villarreal-Gómez, Nancy Reynoso-Noverón
OBJECTIVE: To evaluate the prognostic factors (clinicalpathological characteristics and treatments) in patients with breast cancer and metastasis to central nervous system (CNS) as the first site of the disease. MATERIAL AND METHODS: Kaplan-Meier method and life tables were used to estimate overall survival time over a retrospective cohort of 125 breast cancer patients treated at the Instituto Nacional de Cancerología (INCan) during 2007-2015, who presented metastasis to the CNS as the first site of extension of the disease...
March 2018: Salud Pública de México
https://www.readbyqxmd.com/read/29736850/contralateral-parenchymal-enhancement-on-dynamic-contrast-enhanced-mri-reproduces-as-a-biomarker-of-survival-in-er-positive-her2-negative-breast-cancer-patients
#10
Bas H M van der Velden, Elizabeth J Sutton, Luca A Carbonaro, Ruud M Pijnappel, Elizabeth A Morris, Kenneth G A Gilhuijs
OBJECTIVES: To assess whether contralateral parenchymal enhancement reproduces as an independent biomarker for patient survival in an independent patient cohort from a different cancer institution. METHODS: This is a HIPAA-compliant IRB approved retrospective study. Patients with ER-positive/HER2-negative operable invasive ductal carcinoma and preoperative dynamic contrast-enhanced MRI were consecutively included between 2005 and 2009. The parenchyma of the breast contralateral to known cancer was segmented automatically on MRI and contralateral parenchymal enhancement (CPE) was calculated...
May 7, 2018: European Radiology
https://www.readbyqxmd.com/read/29734483/role-of-dynamic-contrast-enhanced-mri-in-evaluating-the-association-between-contralateral-parenchymal-enhancement-and-survival-outcome-in-er-positive-her2-negative-node-negative-invasive-breast-cancer
#11
Gi Won Shin, Yang Zhang, Min Jung Kim, Min-Ying Su, Eun-Kyung Kim, Hee Jung Moon, Jung Hyun Yoon, Vivian Youngjean Park
BACKGROUND: Background parenchymal enhancement (BPE) on dynamic contrast-enhanced (DCE)-MRI has been associated with breast cancer risk, both based on qualitative and quantitative assessments. PURPOSE: To investigate whether BPE of the contralateral breast on preoperative DCE-MRI is associated with therapy outcome in ER-positive, HER2-negative, node-negative invasive breast cancer. STUDY TYPE: Retrospective. POPULATION: In all, 289 patients with unilateral ER-positive, HER2-negative, node-negative breast cancer larger than 5 mm...
May 7, 2018: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/29722058/breast-cancer-intra-tumour-heterogeneity-current-status-and-clinical-implications
#12
REVIEW
Chitra Joseph, Athanasia Papadaki, Maryam Althobiti, Mansour Alsaleem, Mohammed A Aleskandarany, Emad A Rakha
Breast cancer (BC) is a heterogeneous disease that varies in presentation, morphological features, behaviour and response to therapy. High throughput molecular profiling studies have revolutionised our understanding of BC heterogeneity and demonstrated that molecular portraits of tumours are not only variable between tumours but also within individual tumours. Current evidence indicates that spatial and temporal intra-tumour heterogeneity of BC exists at levels beyond common anticipations. Intra-tumoural heterogeneity poses critical challenges in the diagnosis, prediction of behaviour and management of BC...
May 2, 2018: Histopathology
https://www.readbyqxmd.com/read/29721472/practical-consensus-recommendations-on-management-of-hr-ve-early-breast-cancer-with-specific-reference-to-genomic-profiling
#13
S Aggarwal, A Vaid, A Ramesh, Purvish M Parikh, S Purohit, B Avasthi, S Gupta, S Ranjan, V Kaushal, S Salim, R Singh, S Minhas, D Doval
Breast cancer is a heterogeneous disease and patients are managed clinically based on ER, PR, HER2 expression, and key risk factors. The use of gene expression assays for early stage disease is already common practice. These tests have found a place in risk stratifying the heterogeneous group of stage I-II breast cancers for recurrence, for predicting chemotherapy response, and for predicting breast cancer-related mortality. Most guidelines for hormone receptor (HR)-positive early breast cancer recommend addition of adjuvant chemotherapy for most women, leading to overtreatment, which causes considerable morbidity and cost...
April 2018: South Asian Journal of Cancer
https://www.readbyqxmd.com/read/29719816/local-and-regional-breast-cancer-recurrences-salvage-therapy-options-in-the-new-era-of-molecular-subtypes
#14
REVIEW
Yazid Belkacemi, Nivin E Hanna, Clementine Besnard, Soufya Majdoul, Joseph Gligorov
Isolated local or regional recurrence of breast cancer (BC) leads to an increased risk of metastases and decreased survival. Ipsilateral breast recurrence can occur at the initial tumor bed or in another quadrant of the breast. Depending on tumor patterns and molecular subtypes, the risk and time to onset of metastatic recurrence differs. HER2-positive and triple-negative (TNG) BC have a risk of locoregional relapse between six and eight times than luminal A. Thus, the management of local and locoregional relapses must take into account the prognostic factors for metastatic disease development...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29718092/updated-results-from-monaleesa-2-a-phase-iii-trial-of-first-line-ribociclib-plus-letrozole-versus-placebo-plus-letrozole-in-hormone-receptor-positive-her2-negative-advanced-breast-cancer
#15
G N Hortobagyi, S M Stemmer, H A Burris, Y S Yap, G S Sonke, S Paluch-Shimon, M Campone, K Petrakova, K L Blackwell, E P Winer, W Janni, S Verma, P Conte, C L Arteaga, D A Cameron, S Mondal, F Su, M Miller, M Elmeliegy, C Germa, J O'Shaughnessy
Background: The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. Here we report updated efficacy and safety data, together with exploratory biomarker analyses, from the MONALEESA-2 study. Patients and methods: A total of 668 postmenopausal women with HR+, HER2- recurrent/metastatic breast cancer were randomized (1:1; stratified by presence/absence of liver and/or lung metastases) to ribociclib (600 mg/day; 3-weeks-on/1-week-off; 28-day treatment cycles) plus letrozole (2...
April 27, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29714680/intratumoral-spatial-heterogeneity-at-perfusion-mr-imaging-predicts-recurrence-free-survival-in-locally-advanced-breast-cancer-treated-with-neoadjuvant-chemotherapy
#16
Jia Wu, Guohong Cao, Xiaoli Sun, Juheon Lee, Daniel L Rubin, Sandy Napel, Allison W Kurian, Bruce L Daniel, Ruijiang Li
Purpose To characterize intratumoral spatial heterogeneity at perfusion magnetic resonance (MR) imaging and investigate intratumoral heterogeneity as a predictor of recurrence-free survival (RFS) in breast cancer. Materials and Methods In this retrospective study, a discovery cohort (n = 60) and a multicenter validation cohort (n = 186) were analyzed. Each tumor was divided into multiple spatially segregated, phenotypically consistent subregions on the basis of perfusion MR imaging parameters. The authors first defined a multiregional spatial interaction (MSI) matrix and then, based on this matrix, calculated 22 image features...
April 27, 2018: Radiology
https://www.readbyqxmd.com/read/29700392/ephb6-augments-both-development-and-drug-sensitivity-of-triple-negative-breast-cancer-tumours
#17
Behzad M Toosi, Amr El Zawily, Luke Truitt, Matthew Shannon, Odette Allonby, Mohan Babu, John DeCoteau, Darrell Mousseau, Mohsin Ali, Tanya Freywald, Amanda Gall, Frederick S Vizeacoumar, Morgan W Kirzinger, C Ronald Geyer, Deborah H Anderson, TaeHyung Kim, Alana L Welm, Peter Siegel, Franco J Vizeacoumar, Anthony Kusalik, Andrew Freywald
Triple-negative breast cancer (TNBC) tumours that lack expression of oestrogen, and progesterone receptors, and do not overexpress the HER2 receptor represent the most aggressive breast cancer subtype, which is characterised by the resistance to therapy in frequently relapsing tumours and a high rate of patient mortality. This is likely due to the resistance of slowly proliferating tumour-initiating cells (TICs), and understanding molecular mechanisms that control TICs behaviour is crucial for the development of effective therapeutic approaches...
April 27, 2018: Oncogene
https://www.readbyqxmd.com/read/29685879/clinicopathological-risk-factors-for-an-invasive-breast-cancer-recurrence-after-ductal-carcinoma-in-situ-a-nested-case-control-study
#18
Lindy L Visser, Lotte E Elshof, Michael Schaapveld, Koen Van de Vijver, Emma J Groen, Mathilde M Almekinders, Carolien Bierman, Flora E Van Leeuwen, Emiel J T Rutgers, Marjanka K Schmidt, Esther H Lips, Jelle Wesseling
PURPOSE: Ductal carcinoma in situ (DCIS) is treated to prevent progression to invasive breast cancer. Yet, most lesions will never progress, implying that overtreatment exists. Therefore, we aimed to identify factors distinguishing harmless from potentially hazardous DCIS using a nested case-control study. EXPERIMENTAL DESIGN: We conducted a case-control study nested in a population-based cohort of DCIS patients treated with breast conserving surgery (BCS) alone (n=2,658) between 1989-2005...
April 23, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29684522/microcalcifications-in-breast-cancer-from-pathophysiology-to-diagnosis-and-prognosis
#19
REVIEW
S O'Grady, M P Morgan
The implementation of mammographic screening programmes in many countries has been linked to a marked increase in early detection and improved prognosis for breast cancer patients. Breast tumours can be detected by assessing several features in mammographic images but one of the most common are the presence of small deposits of calcium known as microcalcifications, which in many cases may be the only detectable sign of a breast tumour. In addition to their efficacy in the detection of breast cancer, the presence of microcalcifications within a breast tumour may also convey useful prognostic information...
April 20, 2018: Biochimica et Biophysica Acta
https://www.readbyqxmd.com/read/29684420/novel-cancer-gene-variants-and-gene-fusions-of-triple-negative-breast-cancers-tnbcs-reveal-their-molecular-diversity-conserved-in-the-patient-derived-xenograft-pdx-model
#20
Jaeyun Jung, Kiwon Jang, Jung Min Ju, Eunji Lee, Jong Won Lee, Hee Jung Kim, Jisun Kim, Sae Byul Lee, Beom Seok Ko, Byung Ho Son, Hee Jin Lee, Gyungyup Gong, Sei Yeon Ahn, Jung Kyoon Choi, Shree Ram Singh, Suhwan Chang
Despite the improved 5-year survival rate of breast cancer, triple-negative breast cancer (TNBC) remains a challenge due to lack of effective targeted therapy and higher recurrence and metastasis than other subtypes. To identify novel druggable targets and to understand its unique biology, we tried to implement 24 patient-derived xenografts (PDXs) of TNBC. The overall success rate of PDX implantation was 45%, much higher than estrogen receptor (ER)-positive cases. Immunohistochemical analysis revealed conserved ER/PR/Her2 negativity (with two exceptions) between the original and PDX tumors...
April 20, 2018: Cancer Letters
keyword
keyword
115348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"